Moderna Tumbles Amid Insider Sales and Covid Vaccine Jitters

(Bloomberg) -- Moderna Inc. shares slid 3.5% on Friday as unease mounted about the biotech’s Covid-19 vaccine trial fueled by ongoing insider shares sales and an enrollment slowdown.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.